Pascal Soriot made his name at AstraZeneca by saying no to Pfizer.
Pascal Soriot made his name at AstraZeneca by saying no to Pfizer. He rejected a $118 billion hostile bid in 2014 and proved the company could succeed on its own. Now reports suggest a major shift. The Financial Times says AstraZeneca and Bristol Myers Squibb are in merger talks. The combined value would be about $400 billion.
Discussions have gone on for months. Neither firm has confirmed this. The deal could still fail.
The numbers are simple. AstraZeneca is worth around $263 billion. Bristol Myers Squibb trades near $133 billion. A merger would create the fourth largest drugmaker by market cap. Investor reactions show mixed feelings. AstraZeneca shares fell more than 4% on the news. Bristol Myers Squibb shares rose over 5%. Analysts seem confused. That is rarely a good sign for deal certainty.
Both companies have large oncology units. This makes antitrust review certain. Regulators do not like consolidation in cancer drugs. Approval would likely require selling off assets.
AstraZeneca spent years promoting independence as a key strength. This reported reversal suggests the board now sees scale as essential. Is this true strategic belief? Or is it an admission that standalone growth has stalled? That question remains open.
Not financial advice. For informational and educational purposes only.
$DECK daily pick: sell Dec 18 $75 put (buy-side)
$DECK: I'm selling the Dec 18 $75 put and getting paid to wait on the @hoka and @UGG owner. As of Friday's close ($81.09, markets are closed today): 19% below the 200-day and 34% off the February high Credit $1.90 for ~2.5% in 54 days (~17% annualized) Breakeven $73.10, about 10% below Friday About 10.5x this fiscal year's EPS estimate…
S&P 500 up after all 19 midterms since 1950; at a 70% base rate that streak is roughly 1 in 880
With US midterms on November 3, traders are sharing the stat that the S&P 500 rose in the 12 months after all 19…
S&P Global US Manufacturing PMI hits 56.0 in October, beating the 55.5 consensus by half a point
US manufacturing PMI hit 56.0 in October, the highest since May 2022. The Street expected a dip. Factory hiring was…
Energy Leads Alone as Defensives Lag
Energy led all sectors at +2.60%, more than five times the next-best gain in Information Technology (+0.49%), while eight of eleven sectors finished negative.
Energy returned +2.60% in Friday's session, the largest gain among all tracked sectors and more than five times the next-best, Information Technology at +0.49%. Only three of eleven sectors finished positive, with Real Estate barely in the green at +0.12%. The narrowness…